Tyrosine Kinase Inhibitors for treating ALK mutation-positive advanced non-small-cell lung cancer

Published on 04 Jan 2022
Last Updated on 31 Aug 2022

Tyrosine Kinase Inhibitors for treating ALK-mutation-positive advanced non-small-cell lung cancer Guidance is outdated and has been withdrawn on 12 July 2022. The Plain English Summary (PES) has been updated on 31 August 2022.

Treatments for ALK mutation-positive advanced NSCLC PES (Updated 31 Aug 22) [PDF, 84 KB]

TKIs for ALK mutation-positive advanced NSCLC (Withdrawn 12 Jul 22) [PDF, 193 KB]